Determination of Immune Phenotype in Glioblastoma Patients
NCT ID: NCT02751138
Last Updated: 2023-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2016-03-01
2023-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunophenotyping From Blood of Patients With Malignant Gliomas
NCT02022384
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
NCT03115138
Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas
NCT02379572
An Integrated Radio-immunological Approach
NCT05267509
Gut Microbiota and Glioblastoma Multiforme Prognosis
NCT03631823
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Isocitrate dehydrogenase - 1 mutated
Immunophenotype of Glioblastoma and correlation with outcome
Surgery
Tumor resection
Isocitrate dehydrogenase - 1 wild type
Immunophenotype of Glioblastoma and correlation with outcome
Surgery
Tumor resection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgery
Tumor resection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Ulm
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrej Pala
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurosurgery
Ulm, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
University Hospital Ulm
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.